Development of a decision flowchart to identify the patients need high-dose vancomycin in early phase of treatment

[1]  Kazuaki Matsumoto,et al.  The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing , 2021, BMC Infectious Diseases.

[2]  H. Ikeuchi,et al.  Vancomycin loading dose is associated with increased early clinical response without attainment of initial target trough concentration at a steady state in patients with methicillin‐resistant Staphylococcus aureus infections , 2020, Journal of clinical pharmacy and therapeutics.

[3]  D. Levine,et al.  Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Socie , 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  M. C. Morales-Alvarez.  Nephrotoxicity of Antimicrobials and Antibiotics. , 2020, Advances in chronic kidney disease.

[5]  H. Jono,et al.  Development and evaluation of a vancomycin dosing nomogram to achieve the target area under the concentration-time curve. A retrospective study. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  M. Postelnick,et al.  Vancomycin Area under the Curve and Acute Kidney Injury: A Meta-analysis. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Lee P. Skrupky,et al.  Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections. , 2019, Therapeutic drug monitoring.

[8]  K. Itoh,et al.  Validation of a Nomogram for Achieving Target Trough Concentration of Vancomycin: Accuracy in Patients With Augmented Renal Function , 2018, Therapeutic drug monitoring.

[9]  N. Takamura,et al.  Establishment of a new initial dose plan for vancomycin using the generalized linear mixed model , 2017, Theoretical Biology and Medical Modelling.

[10]  S. Goutelle,et al.  Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Clinical Study in Elderly Patients , 2017, Therapeutic drug monitoring.

[11]  E. Korgenski,et al.  AUC‐Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis , 2016, Journal of clinical pharmacology.

[12]  F. Vrtovsnik,et al.  Creatinine-based equations for the adjustment of drug dosage in an obese population. , 2016, British journal of clinical pharmacology.

[13]  Naoto Okada,et al.  Clinical Evaluation of Pharmacist Interventions in Patients Treated with Anti-methicillin-Resistant Staphylococcus aureus Agents in a Hematological Ward. , 2016, Biological & pharmaceutical bulletin.

[14]  M. Papas,et al.  A Randomized Trial of Loading Vancomycin in the Emergency Department , 2015, The Annals of pharmacotherapy.

[15]  J. Roberts,et al.  Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds , 2014, Critical Care.

[16]  A. Udy,et al.  Select Critically ill Patients at Risk of Augmented Renal Clearance: Experience in a Malaysian Intensive Care Unit , 2014, Anaesthesia and intensive care.

[17]  T. Khadem,et al.  A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. , 2013, Clinical therapeutics.

[18]  T. Fukuda,et al.  Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis , 2013, Intensive Care Medicine.

[19]  T. Fukuda,et al.  Decreased vancomycin clearance in patients with congestive heart failure , 2013, European Journal of Clinical Pharmacology.

[20]  J. Turnidge,et al.  Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia , 2013, Antimicrobial Agents and Chemotherapy.

[21]  H. Chien,et al.  Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[22]  A. Khwaja.  KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[23]  S. Matsubara,et al.  Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[24]  Lei Zhang,et al.  The Influence of Body Size Descriptors on the Estimation of Kidney Function in Normal Weight, Overweight, Obese, and Morbidly Obese Adults , 2012, The Annals of pharmacotherapy.

[25]  J. Leggett,et al.  Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. , 2010, The American journal of medicine.

[26]  A. Martín-Suárez,et al.  Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. , 2010, British journal of clinical pharmacology.

[27]  G. Drusano,et al.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  A. Pai,et al.  Estimation of creatinine clearance in morbidly obese patients. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[29]  M. Cirillo,et al.  Relationship of gender, age, and body mass index to errors in predicted kidney function. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  J. Rotschafer,et al.  Evaluation of a Two‐Compartment Bayesian Forecasting Program for Predicting Vancomycin Concentrations , 1989, Therapeutic drug monitoring.

[31]  G. Matzke,et al.  Clinical Pharmacokinetics of Vancomycin , 1986, Clinical pharmacokinetics.

[32]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[33]  Y. Takekuma,et al.  A New Algorithm Optimized for Initial Dose Settings of Vancomycin Using Machine Learning. , 2020, Biological & pharmaceutical bulletin.

[34]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[35]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[38]  T. Iga,et al.  Population pharmacokinetics of vancomycin in Japanese adult patients. , 1998, Therapeutic drug monitoring.